Organization | Center for Human Reproduction

Center for Human Reproduction Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: New York NY United States (1981)

Organization Overview

First Clinical Trial

2007

NCT00419913

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

David H. Barad

Active Ingredients

Drugs in Phase 4 Trials (4)

follitropin alfa (Gonal-F) (2 trials)

inactivated influenza vaccine (2 trials)

letrozole (femara) (1 trial)

menopausal gonadotropin (1 trial)

Drugs in Phase 3 Trials (1)

prasterone (intrarosa) (3 trials)

Drugs in Phase 2 Trials (5)

dehydroepiandrosterone (1 trial)

sargramostim (leukine) (2 trials)

sodium chloride (2 trials)

somatropin (protropin) (1 trial)

testosterone (delatestryl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Abortion, Habitual (Phase 4)

Abortion, Spontaneous (Phase 4)

Infertility (Phase 4)

Infertility, Female (Phase 2)

Menopause, Premature (Phase 3)

Premature Birth (Phase 3)

Primary Ovarian Insufficiency (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 11
# of Trial APIs: 10